Attached files
| file | filename |
|---|---|
| 10-Q - FORM 10-Q - Vaxart, Inc. | avir20170930_10q.htm |
| EX-31.2 - EXHIBIT 31.2 - Vaxart, Inc. | ex_98261.htm |
| EX-31.1 - EXHIBIT 31.1 - Vaxart, Inc. | ex_98260.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q of Aviragen Therapeutics, Inc. (“the Company”) for the quarterly period ended September 30, 2017 (the “Report”), I, Joseph M. Patti, Chief Executive Officer of the Company, and Mark P. Colonnese, Chief Financial Officer of the Company each certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
|
|
● |
To my knowledge, the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
|
|
● |
The information in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
|
Dated: November 7, 2017 |
By: |
/s/ Joseph M. Patti |
|
|
|
Joseph M. Patti |
|
|
|
Chief Executive Officer |
|
|
|
(Principal Executive Officer) |
|
|
|
|
|
|
|
|
|
|
By: |
/s/ Mark P. Colonnese |
|
|
|
Mark P. Colonnese |
|
|
|
Chief Financial Officer |
|
|
|
(Principal Financial Officer) |